top of page
Lead Product: ACTM-838
Our lead asset, ACTM-838, delivers a powerful 1,2-punch by combining two immune-activating agents that elicit a potent effect. Our pre-clinical studies have demonstrated reprogramming of the tumor immune state, the eradication of solid tumors, and protection against tumor rechallenging, indicating a strikingly successful anti-tumor memory response by the adaptive immune system. ACTM-838 is advancing through the clinic and is currently in a Phase 1a/b trial.
We believe the STACT™ platform will become an indispensable tool for achieving tipping point efficacy of IO drugs – something that still largely eludes the field of oncology.
Our pipeline is built on the STACT™ platform, through which we deploy the biological intelligence of bacteria to treat the untreatable, beginning with cancer. Our pipeline is built on the STACT™ platform, through which we deploy the biological intelligence of bacteria to treat the untreatable, beginning with cancer. Our pipeline is built on the STACT™ platform, through which we deploy the biological intelligence of bacteria to treat the untreatable, beginning with cancer. Our pipeline is built on the STACT™ platform, through which we deploy the biological intelligence of bacteria to treat the untreatable, beginning with cancer.
Oncology
Fibrosis
Undisclosed
ACTM-838
Advanced Solid Tumors
Indication
Discovery
IND-Enabling
Phase 1
Program
Phase 2
Program
Indication
Discovery
IND-
Enabling
Phase 1
Phase 2
Advanced Solid Tumors
ACTM-838
Undisclosed
Oncology
Undisclosed
Fibrosis
bottom of page